Showing 3461-3470 of 18631 results for "".
Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
https://reachmd.com/programs/cme/navigating-treatment-sequencing-after-frontline-treatment-failure-in-cll/39260/Dr. Jennifer Brown discusses CLL treatment sequencing after frontline failure, including resistance vs intolerance, MRD-guided strategies, and second-line therapy decisions.Sustained Antidepressant and Sleep Benefits With Adjunctive Seltorexant in MDD: Double-Blind and Long-Term Extension Data From the MD3001 Trial
https://reachmd.com/clinical-practice/psychiatry-and-mental-health/sustained-antidepressant-and-sleep-benefits-with-adjunctive-seltorexant-in-mdd-double-blind-and-long-term-extension-data-from-the-md3001-trial/36555/Review Phase 3 MD3001 trial data on adjunctive seltorexant in MDD with insomnia, including double-blind efficacy and 1-year extension safety outcomes.Chemotherapy Strategies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
https://reachmd.com/programs/cme/chemotherapy-strategies-in-metastatic-pancreatic-ductal-adenocarcinoma-pdac/32377/Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes, and awareness of risk facDouble-Class Refractory CLL in Community Practice: Current and Future Management
https://reachmd.com/programs/cme/double-class-refractory-cll-in-community-practice-current-and-future-management/39261/Explore expert-guided strategies for managing double-class-refractory CLL, including BTK resistance, treatment sequencing, and emerging therapeutic options.Chairperson Perspective: Core Concepts for Community-Based Practice: The Evolving Role of Bispecific Antibody Therapy in Relapsed or Refractory Follicular Lymphoma
https://reachmd.com/programs/cme/chairperson-perspective-core-concepts-for-community-based-practice-the-evolving-role-of-bispecific-antibody-therapy-in-relapsed-or-refractory-follicular-lymphoma/29191/This educational activity will examine evidence-based strategies that improve treatment outcomes, enhance patient safety, and improve the overall quality of care for R/R FL patients receiving bispecific antibody therapy.Cases From the Real World: 72-Year-Old Woman With CRVO
https://reachmd.com/programs/cme/Cases-From-the-Real-World-72-Year-Old-Woman-With-CRVO/33171/Hear how Drs. Ferhina Ali and Yasha Modi navigate the balance of extending treatment intervals while reducing the risk of recurrent ME in RVO.Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
https://reachmd.com/programs/cme/antibody-drug-conjugates-in-bladder-cancer-guideline-updates-and-adverse-event-management/29174/Learn the latest treatment guidelines for metastatic bladder cancer and hear updates on emerging immunotherapies for muscle-invasive bladder cancer.Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
https://reachmd.com/programs/cme/early-approaches-to-ras-targeting-efficacy-signals-and-known-limitations/54119/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Molecular Profiling as a Cornerstone of Precision AML Therapy
https://reachmd.com/programs/cme/molecular-profiling-as-a-cornerstone-of-precision-aml-therapy/36178/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.Duration of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
https://reachmd.com/programs/cme/duration-of-ovarian-function-suppression-in-premenopausal-hr-early-stage-breast-cancer/32908/Optimize ovarian function suppression in HR+ early-stage breast cancer with expert insights on timing and duration to enhance patient outcomes.